Skip to main navigation
Leap therapeutics
Leap therapeutics
  • About
    • About
    • Contact Us
  • Pipeline
    • Pipeline
    • DKN-01 programs
      • Gastric Cancer
      • Colorectal Cancer
      • Endometrial Cancer
      • Prostate Cancer
      • Lung Cancer
    • Anti-CLDN18.2 programs
      • FL-301 (NBL-015)
      • FL-302 (NBL-016)
    • FL-501
  • Science
    • Science
    • DKK1
    • DKN-01
    • Claudin18.2
    • GDF15
  • Patients
    • Patients
    • Expanded Access
  • Careers
  • Investors
    • Investors
    • Stock Information
    • News Releases
    • Presentations & Events
    • Financial Information
    • Corporate Governance
    • Information Request

SEC
Filing

image description

Document Details

Form
CORRESP
Filing Date
Nov 1, 2016
Document Date
Nov 1, 2016
Form Description
CORRESP
Filing Group
Other
Company
Leap Therapeutics, Inc.
Issuer
LEAP THERAPEUTICS, INC.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
  • image Print Page Print Page
  • image Email Alerts Email Alerts
  • image Contact Us Contact Us
image description
image description
Leap therapeutics
47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 USA
+1 617 714 0360

Business inquiries
bd@leaptx.com

Investor inquiries
ir@leaptx.com

  • ABOUT
  • CONTACT US
  • CAREERS
  • PIPELINE
  • DKN-01 PROGRAMS
  • ANTI-CLDN18.2 PROGRAMS
  • FL-501
  • PATIENTS
  • EXPANDED ACCESS
  • SCIENCE
  • DKK1
  • DKN-01
  • CLAUDIN18.2
  • GDF15
  • INVESTORS
  • STOCK INFORMATION
  • NEWS RELEASES
  • PRESENTATIONS & EVENTS
  • FINANCIAL INFORMATION
  • CORPORATE GOVERNANCE
  • INFORMATION REQUEST
  • © 2023 Leap Therapeutics, Inc.
  • All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • Cookie Policy